Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBITDA (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed EBITDA for 8 consecutive years, with -$75.2 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA fell 17.26% year-over-year to -$75.2 million; the TTM value through Mar 2026 reached -$319.1 million, down 33.44%, while the annual FY2025 figure was -$308.1 million, 37.05% down from the prior year.
  • EBITDA hit -$75.2 million in Q1 2026 for Kymera Therapeutics, up from -$86.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.5 million in Q4 2023 and bottomed at -$86.7 million in Q4 2025.
  • Average EBITDA over 5 years is -$53.5 million, with a median of -$49.8 million recorded in 2024.
  • Year-over-year, EBITDA soared 63.22% in 2023 and then tumbled 494.77% in 2024.
  • Kymera Therapeutics' EBITDA stood at -$33.9 million in 2022, then soared by 63.22% to -$12.5 million in 2023, then crashed by 494.77% to -$74.2 million in 2024, then decreased by 16.87% to -$86.7 million in 2025, then increased by 13.21% to -$75.2 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$75.2 million, -$86.7 million, and -$81.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.